Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Psychiatry/Psychology | Neurology
Disease Category: Schizophrenia and Schizoaffective Disorders
Location: United States, IL
Clinical Trial Details
Research Study Summary
A phase 2, multicenter, double-blind placebo-controlled comparator study of 2 doses of LY2140023 versus placebo in patients with DSM-IV-TR Schizophrenia.
The primary purpose of your participation in this study is to help answer the following research question(s), and not to provide you treatment for your condition:
- Whether LY2140023 can help subjects/patients with schizophrenia.
- Whether LY2140023 can help subjects/patients with schizophrenia who have certain DNA.
You must be willing and able to stay in the hospital for a minimum of 21 days.
Please contact Alexian Brothers for more information on participation.
To Learn more
Both Male and Female
Date Last Changed:
July 22, 2013
DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the
clinical trials industry. The information provided in this service is designed
to help patients find clinical trials that may be of interest to them, and to
help patients contact the centers conducting the research. CenterWatch is
neither promoting this research nor involved in conducting any of these